ANEB Anebulo Pharmaceuticals Inc: רווח נקי למניה ב-12 החודשים האחרונים

Anebulo Pharmaceuticals (ANEB) bases its biotech business on the development of ANEB-001, an innovative treatment for emergency cannabinoid overdose assistance. Narrow specialization and a lack of alternatives promise stable revenue from the patented drug. This chart reflects a price trend for EPS (TTM) currently at 33.40. However, future pricing power will depend on test results and the FDA verdict.
Anebulo Pharmaceuticals - פילוחים אנליטיים ומדדי מפתח (ANEB)

This indicator measures the rate of change in net income per share over the last twelve months, reflecting the actual monetization efficiency of the business model. By analyzing the annual EPS (TTM) change on GURU.Markets, an investor can assess the impact of the Fast Track status of the ANEB-001 drug and the lack of competition on the capitalization of Anebulo Pharmaceuticals (ANEB) through the lens of actual income dynamics.